Regulatory authorities in the US and EU have taken further steps to align their practices in light of the coronavirus pandemic. Officials from the two regions already hold regular conversations about issues relating to the authorisation of new medicines. Now they are broadening their discussions to consult on pandemic issues such as the use of real world evidence to better understand the epidemiology of COVID-19.
